News image

Market researchers need if possible to collect the patient/consumer’s contact details and forward these details to the Marketing Authorisation Holder’s (MAH) pharmacovigilance (PV) team to follow up where needed. This change was implemented to allow PV to meet their European Medicines Agency (EMA) obligations. Please refer to the BHBIA website for details of the Guidance notes.
After careful consideration, EphMRA recommends this process should be followed for healthcare market research conducted in European Union (EU) countries including UK to allow PV to meet their EMA obligations.